PT  - JOURNAL ARTICLE
AU  - Merz, Simon F.
AU  - Jansen, Philipp
AU  - Ulankiewicz, Ricarda
AU  - Bornemann, Lea
AU  - Schimming, Tobias
AU  - Griewank, Klaus
AU  - Cibir, Zülal
AU  - Kraus, Andreas
AU  - Stoffels, Ingo
AU  - Aspelmeier, Timo
AU  - Brandau, Sven
AU  - Schadendorf, Dirk
AU  - Hadaschik, Eva
AU  - Ebel, Gernot
AU  - Gunzer, Matthias
AU  - Klode, Joachim
TI  - High-resolution 3-D imaging for precise staging in malignant melanoma
AID  - 10.1101/2020.07.22.20159103
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.07.22.20159103
4099  - http://medrxiv.org/content/early/2020/07/25/2020.07.22.20159103.short
4100  - http://medrxiv.org/content/early/2020/07/25/2020.07.22.20159103.full
AB  - High-resolution imaging of sentinel lymph nodes (SLN) from melanoma patients is a crucial approach to specify staging and determine individuals requiring adjuvant treatment. Current histologic SLN analysis has the substantial drawback that only a small portion of the node is sampled while most of the tissue is discarded which might explain the high false-negative rate of SLN diagnosis. Therefore, we developed an algorithm-enhanced light sheet fluorescence microscopy (LSFM) approach to three-dimensionally reconstruct the entire SLN with the power to identify single tumor cells. We comprehensively quantified total tumor volume while simultaneously visualizing cellular and anatomical hallmarks of the associated SLN architecture. In a first-in-human prospective study (21 SLN from 11 melanoma patients), LSFM not only identified all metastases seen histologically, but additionally detected metastases not recognized by routine histology. Thus, our 3-D digital pathology approach can increase sensitivity and accuracy of SLN-metastasis detection and potentially alleviate the need for conventional histopathological assessment in the future.Competing Interest StatementGE is currently employed by LaVision BioTec GmbH, a Miltenyi company. MG and JK received general research funding from LaVision BioTec GmbH. The remaining authors declare no competing interests.Clinical TrialUTN: U1111-1222-2725 German Clinical Trial registry: DRKS00015737Funding StatementMG and JK received general research funding from LaVision BioTec GmbH.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This prospective study was approved by the local ethics committee of the Medical Faculty, University Hospital Essen, Germany (17-7420-BO).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSource data for all figures based in the paper based on Imaris quantification is available [https://doi.org/10.17185/duepublico/71558]. Raw LSFM data is available upon request. https://doi.org/10.17185/duepublico/71558